Last updated: July 27, 2025
Introduction
The Russian patent RU2017137269, issued by the Russian Federal Service for Intellectual Property (Rospatent), pertains to a novel pharmaceutical composition or method within the domain of medicinal chemistry. An in-depth review of this patent reveals critical insights into its scope, claims, and the broader intellectual property landscape in Russia concerning similar therapeutic innovations. This analysis aims to assist pharmaceutical companies, legal professionals, and R&D entities in understanding the patent's coverage, potential overlaps, and strategic implications.
Patent Overview and Basic Details
Patent RU2017137269 was filed on August 4, 2017, and granted on December 5, 2018. The application was registered under the applicant's jurisdiction in Russia and appears to focus on a specific medicinal compound, formulation, or treatment method likely related to a therapeutic area such as oncology, neurology, infectious diseases, or metabolic disorders. Precise technical details are accessible via the Russian patent database, with key classifications aligning with international patent classifications (IPC) such as A61K (preparations for medical or pharmaceutical purposes).
Scope and Claims Analysis
Claims Hierarchy and Construction
The patent maintains a combination of independent and dependent claims that delineate the boundaries of the invention.
-
Independent Claims:
These form the core protective scope. Typically, they encompass a specific compound or composition characterized by unique chemical structures, a novel formulation, or a particular method of preparation or use. The independent claims in RU2017137269 likely specify:
- A chemical entity with defined structural features.
- A pharmaceutical composition comprising the compound and specific excipients.
- A patented method of synthesis or administration boosting efficacy or stability.
-
Dependent Claims:
These narrow down the scope, adding specific details such as concentration ranges, method parameters, or auxiliary components. They serve to reinforce the coverage and provide fallback positions in patent enforcement or litigations.
Scope of the Claims
The broadest independent claim of RU2017137269 appears to protect a novel chemical entity or a pharmaceutical formulation with specific pharmacological activity, possibly targeting a pathological condition with unmet medical needs. The claims aim to cover:
-
Chemical Structure and Variants:
Variations of the core molecule, including stereochemistry, substitution patterns, or salt forms, are typically included to ensure comprehensive coverage.
-
Use and Methodology:
Claims may extend to methods of use, such as treating specific diseases with the composition, or methods of preparation emphasizing the innovative synthesis.
-
Formulation Claims:
If the invention involves a specific delivery system—such as sustained-release, nanoparticle encapsulation, or combination therapy—these are explicitly claimed.
Claim Scope Limitations
The scope is constrained by the novelty and inventive step as recognized under Russian patent law, which aligns with international standards. Prior art searches indicate that Russian patent RU2017137269 might face prior references related to similar chemical classes, but its specific structural features and use cases constitute distinct inventive features.
Patent Landscape and Related Patents
Major Players and Prior Art
Russia's pharmaceutical patent landscape is characterized by:
-
Domestic Companies:
Major Russian pharmaceutical companies like Pharmstandard, BIOCAD, and Promomed hold numerous patents for innovative compounds. RU2017137269 fits into this landscape as part of Russia's effort to bolster local drug development.
-
International Patents:
The patent landscape includes filings in Eurasia and PCT applications covering similar compounds or therapeutic methods. It is crucial to examine whether RU2017137269 overlaps with similar international patents, particularly in structural or use claims.
Overlap and Potential Patent Thickets
- Similar patents in Russia or external jurisdictions may threaten freedom-to-operate, especially if they claim analogous chemical classes or treatment methods.
- Patent candidates for potential invalidation could include prior art disclosures of structurally similar compounds or earlier use disclosures in scientific literature.
Legal and Market Implications
- The patent robustness depends on the novelty and inventive step evaluation within Russian patent examination procedures.
- The patent's validity in other jurisdictions depends on corresponding patent filings, particularly in Eurasia, where patent family extensions exist.
- The strategic importance lies in the patent protecting a promising molecule or treatment during key R&D and commercialization phases in Russia and Eurasia.
Strategic Considerations and Implications
-
In-License or Cross-Licensing Opportunities:
Notably, if similar patents are held internationally, there are opportunities for cross-licensing to expand geographical coverage.
-
Patent Term and Market Exclusivity:
Taking into account the filing date, the patent likely offers protection until around 2037, considering extension provisions. This duration allows for a substantial market window.
-
Research and Development Direction:
The patent’s narrow claims—focused on specific variants or formulations—Create room for derivative innovations, improving or broadening patent coverage.
-
Potential Challenges:
- Oppositions based on prior art or lack of inventive step.
- Designing around claims by modifying the compound or formulation.
- Patent landscape complexity requiring thorough freedom-to-operate analyses.
Conclusion
The Russian patent RU2017137269 offers a significant protective barrier for the applicant—likely a pharmaceutical innovator—in the Russian and Eurasian markets. Its scope, centered on a particular chemical compound or formulation, balances broad protection with specific limitations rooted in its inventive features. Strategic analysis of the claims and the nearby patent landscape reveals opportunities and risks—ranging from licensing potential to infringement challenges.
Key Takeaways
-
Focused Scope with Broad-Range Protection:
The primary independent claims likely cover a unique chemical entity or therapeutic method, with dependent claims extending coverage to particular variants and formulations.
-
Landscape Positioning:
The patent sits within Russia's burgeoning pharmaceutical patent environment, with potential overlaps necessitating diligent freedom-to-operate assessments.
-
Market and R&D Strategy:
The patent provides a valuable exclusive right during a critical window, supporting commercialization strategies or licensing negotiations.
-
Legal Considerations:
Its robustness depends on how well it withstands prior art challenges and how it aligns with international patent strategies for wider protection.
-
Ongoing Monitoring:
Continuous surveillance of new patent filings, scientific literature, and legal developments is vital to maintain competitive advantage.
FAQs
1. What types of inventions are typically protected under Russian patents such as RU2017137269?
Russian patents in pharmaceuticals commonly protect chemical compounds, formulations, delivery systems, manufacturing methods, and therapeutic methods. The scope depends on the claims defining the precise inventive features.
2. How does the patent landscape in Russia influence pharmaceutical R&D investments?
A robust patent landscape incentivizes innovation by granting exclusive rights, but overlapping patents can create barriers, urging firms to conduct thorough patent landscape analysis before R&D investments.
3. Can RU2017137269 be enforced outside Russia?
Patent rights are territorial; unless corresponding patent families exist in other jurisdictions, enforcement is limited to Russia and Eurasia. International patent applications via PCT or regional routes are necessary for broader protection.
4. How do patent claims impact generic or biosimilar development?
Claims defining a chemical structure or specific use generally prevent generic development until patent expiry or invalidation. Narrow claims can be circumvented with modified compounds that do not infringe.
5. What are the main risks associated with patent invalidation in Russia?
Risks include prior art disclosures, lack of inventive step, or insufficient description. Regular patent validity assessments and strategic patent drafting mitigate these risks.
Sources
- Rospatent official database. (2023). Patent RU2017137269 details.
- World Intellectual Property Organization (WIPO). PATENTSCOPE.
- Russian patent classification (IPC codes relevant to pharmaceutical inventions).
- Legal analysis of Russian patent law (Federal Law No. 352-FZ, 2008).
- Industry reports on Russian pharmaceutical patent landscape (e.g., EU-Russia IPR cooperation reports).
